Acute Myeloid Leukemia Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Chemotherapy (Cytarabine, Anthracycline Drugs, Alkylating Agents, Anti-metabolites, Tyrosine Kinase Inhibitors, hormonal therapy, and other chemotherapies), By Region, and Competition, 2020-2030F

December 2025 | 183 pages | ID: A0282F8B6E8AEN
TechSci Research

Abstracts

The Global Acute Myeloid Leukemia Market, valued at USD 1.56 Billion in 2024, is projected to experience a CAGR of 8.90% to reach USD 2.63 Billion by 2030. Acute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood and bone marrow, characterized by the uncontrolled proliferation of abnormal myeloid blast cells. The market for AML therapies is primarily driven by the increasing global incidence of this disease, coupled with an expanding geriatric population which faces a higher risk of diagnosis.

Key Market Drivers

The global Acute Myeloid Leukemia market is significantly propelled by continuous advancements in AML research and therapeutic technologies. These innovations expand treatment options and improve patient outcomes through novel drug classes and therapeutic strategies. For instance, according to The Leukemia & Lymphoma Society, in December 2024, the U. S. Food and Drug Administration approved revumenib, the first-in-class menin inhibitor for adults and children with advanced acute myeloid leukemia presenting KMT2A gene translocations.

Key Market Challenges

The substantial cost associated with advanced therapeutic regimens presents a significant impediment to the growth of the Global Acute Myeloid Leukemia Market. These high expenses directly affect patient access to potentially life-saving treatments, thereby limiting the overall uptake and revenue potential of innovative therapies. Advanced options, such as novel targeted agents and allogeneic stem cell transplantation, carry considerable price tags that can strain healthcare systems and individual patient finances globally.

Key Market Trends

The increasing utilization of oral and outpatient treatment regimens is significantly reshaping the global Acute Myeloid Leukemia market by enhancing patient convenience and reducing the burden on hospital infrastructure. These innovative approaches enable treatment administration in less restrictive settings, improving the quality of life for patients, particularly the elderly or those with comorbidities.

Key Market Players

• Bristol-Myers Squibb Company (Celgene Corporation)
• Novartis AG
• Genmab AS
• Otsuka Holdings Co. Ltd
• Sanofi-Aventis (Genzyme Corporation)
• Teva Pharmaceutical (Cephalon Inc.)
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd
• Sunesis Pharmaceuticals Inc.
• Astellas Pharma
• Oncolyze Inc.

Report Scope:

In this report, the Global Acute Myeloid Leukemia Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Acute Myeloid Leukemia Market, By Chemotherapy:
• Cytarabine
• Anthracycline Drugs
• Alkylating Agents
• Anti-metabolites
• Tyrosine Kinase Inhibitors
• Hormonal therapy
• Other chemotherapies
• Acute Myeloid Leukemia Market, By Region:
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• South America
• Brazil
• Argentina
• Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Acute Myeloid Leukemia Market.

Available Customizations:

Global Acute Myeloid Leukemia Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

1.1. Market Definition
1.2. Scope of the Market
  1.2.1. Markets Covered
  1.2.2. Years Considered for Study
  1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. GLOBAL ACUTE MYELOID LEUKEMIA MARKET OUTLOOK

5.1. Market Size & Forecast
  5.1.1. By Value
5.2. Market Share & Forecast
  5.2.1. By Chemotherapy (Cytarabine, Anthracycline Drugs, Alkylating Agents, Anti-metabolites, Tyrosine Kinase Inhibitors, Hormonal therapy, Other chemotherapies)
  5.2.2. By Region
  5.2.3. By Company (2024)
5.3. Market Map

6. NORTH AMERICA ACUTE MYELOID LEUKEMIA MARKET OUTLOOK

6.1. Market Size & Forecast
  6.1.1. By Value
6.2. Market Share & Forecast
  6.2.1. By Chemotherapy
  6.2.2. By Country
6.3. North America: Country Analysis
  6.3.1. United States Acute Myeloid Leukemia Market Outlook
    6.3.1.1. Market Size & Forecast
      6.3.1.1.1. By Value
    6.3.1.2. Market Share & Forecast
      6.3.1.2.1. By Chemotherapy
  6.3.2. Canada Acute Myeloid Leukemia Market Outlook
    6.3.2.1. Market Size & Forecast
      6.3.2.1.1. By Value
    6.3.2.2. Market Share & Forecast
      6.3.2.2.1. By Chemotherapy
  6.3.3. Mexico Acute Myeloid Leukemia Market Outlook
    6.3.3.1. Market Size & Forecast
      6.3.3.1.1. By Value
    6.3.3.2. Market Share & Forecast
      6.3.3.2.1. By Chemotherapy

7. EUROPE ACUTE MYELOID LEUKEMIA MARKET OUTLOOK

7.1. Market Size & Forecast
  7.1.1. By Value
7.2. Market Share & Forecast
  7.2.1. By Chemotherapy
  7.2.2. By Country
7.3. Europe: Country Analysis
  7.3.1. Germany Acute Myeloid Leukemia Market Outlook
    7.3.1.1. Market Size & Forecast
      7.3.1.1.1. By Value
    7.3.1.2. Market Share & Forecast
      7.3.1.2.1. By Chemotherapy
  7.3.2. France Acute Myeloid Leukemia Market Outlook
    7.3.2.1. Market Size & Forecast
      7.3.2.1.1. By Value
    7.3.2.2. Market Share & Forecast
      7.3.2.2.1. By Chemotherapy
  7.3.3. United Kingdom Acute Myeloid Leukemia Market Outlook
    7.3.3.1. Market Size & Forecast
      7.3.3.1.1. By Value
    7.3.3.2. Market Share & Forecast
      7.3.3.2.1. By Chemotherapy
  7.3.4. Italy Acute Myeloid Leukemia Market Outlook
    7.3.4.1. Market Size & Forecast
      7.3.4.1.1. By Value
    7.3.4.2. Market Share & Forecast
      7.3.4.2.1. By Chemotherapy
  7.3.5. Spain Acute Myeloid Leukemia Market Outlook
    7.3.5.1. Market Size & Forecast
      7.3.5.1.1. By Value
    7.3.5.2. Market Share & Forecast
      7.3.5.2.1. By Chemotherapy

8. ASIA PACIFIC ACUTE MYELOID LEUKEMIA MARKET OUTLOOK

8.1. Market Size & Forecast
  8.1.1. By Value
8.2. Market Share & Forecast
  8.2.1. By Chemotherapy
  8.2.2. By Country
8.3. Asia Pacific: Country Analysis
  8.3.1. China Acute Myeloid Leukemia Market Outlook
    8.3.1.1. Market Size & Forecast
      8.3.1.1.1. By Value
    8.3.1.2. Market Share & Forecast
      8.3.1.2.1. By Chemotherapy
  8.3.2. India Acute Myeloid Leukemia Market Outlook
    8.3.2.1. Market Size & Forecast
      8.3.2.1.1. By Value
    8.3.2.2. Market Share & Forecast
      8.3.2.2.1. By Chemotherapy
  8.3.3. Japan Acute Myeloid Leukemia Market Outlook
    8.3.3.1. Market Size & Forecast
      8.3.3.1.1. By Value
    8.3.3.2. Market Share & Forecast
      8.3.3.2.1. By Chemotherapy
  8.3.4. South Korea Acute Myeloid Leukemia Market Outlook
    8.3.4.1. Market Size & Forecast
      8.3.4.1.1. By Value
    8.3.4.2. Market Share & Forecast
      8.3.4.2.1. By Chemotherapy
  8.3.5. Australia Acute Myeloid Leukemia Market Outlook
    8.3.5.1. Market Size & Forecast
      8.3.5.1.1. By Value
    8.3.5.2. Market Share & Forecast
      8.3.5.2.1. By Chemotherapy

9. MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA MARKET OUTLOOK

9.1. Market Size & Forecast
  9.1.1. By Value
9.2. Market Share & Forecast
  9.2.1. By Chemotherapy
  9.2.2. By Country
9.3. Middle East & Africa: Country Analysis
  9.3.1. Saudi Arabia Acute Myeloid Leukemia Market Outlook
    9.3.1.1. Market Size & Forecast
      9.3.1.1.1. By Value
    9.3.1.2. Market Share & Forecast
      9.3.1.2.1. By Chemotherapy
  9.3.2. UAE Acute Myeloid Leukemia Market Outlook
    9.3.2.1. Market Size & Forecast
      9.3.2.1.1. By Value
    9.3.2.2. Market Share & Forecast
      9.3.2.2.1. By Chemotherapy
  9.3.3. South Africa Acute Myeloid Leukemia Market Outlook
    9.3.3.1. Market Size & Forecast
      9.3.3.1.1. By Value
    9.3.3.2. Market Share & Forecast
      9.3.3.2.1. By Chemotherapy

10. SOUTH AMERICA ACUTE MYELOID LEUKEMIA MARKET OUTLOOK

10.1. Market Size & Forecast
  10.1.1. By Value
10.2. Market Share & Forecast
  10.2.1. By Chemotherapy
  10.2.2. By Country
10.3. South America: Country Analysis
  10.3.1. Brazil Acute Myeloid Leukemia Market Outlook
    10.3.1.1. Market Size & Forecast
      10.3.1.1.1. By Value
    10.3.1.2. Market Share & Forecast
      10.3.1.2.1. By Chemotherapy
  10.3.2. Colombia Acute Myeloid Leukemia Market Outlook
    10.3.2.1. Market Size & Forecast
      10.3.2.1.1. By Value
    10.3.2.2. Market Share & Forecast
      10.3.2.2.1. By Chemotherapy
  10.3.3. Argentina Acute Myeloid Leukemia Market Outlook
    10.3.3.1. Market Size & Forecast
      10.3.3.1.1. By Value
    10.3.3.2. Market Share & Forecast
      10.3.3.2.1. By Chemotherapy

11. MARKET DYNAMICS

11.1. Drivers
11.2. Challenges

12. MARKET TRENDS & DEVELOPMENTS

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. GLOBAL ACUTE MYELOID LEUKEMIA MARKET: SWOT ANALYSIS

14. PORTER'S FIVE FORCES ANALYSIS

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. COMPETITIVE LANDSCAPE

15.1. Bristol-Myers Squibb Company (Celgene Corporation)
  15.1.1. Business Overview
  15.1.2. Products & Services
  15.1.3. Recent Developments
  15.1.4. Key Personnel
  15.1.5. SWOT Analysis
15.2. Novartis AG
15.3. Genmab AS
15.4. Otsuka Holdings Co. Ltd
15.5. Sanofi-Aventis (Genzyme Corporation)
15.6. Teva Pharmaceutical (Cephalon Inc.)
15.7. Pfizer Inc.
15.8. F. Hoffmann-La Roche Ltd
15.9. Sunesis Pharmaceuticals Inc.
15.10. Astellas Pharma
15.11. Oncolyze Inc.

16. STRATEGIC RECOMMENDATIONS

17. ABOUT US & DISCLAIMER